161 related articles for article (PubMed ID: 9125861)
41. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment.
Ick K; Schultz M; Stout P; Fan K
Urology; 1997 Apr; 49(4):541-6; discussion 546-7. PubMed ID: 9111623
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases.
Sallami S; Khouni H; Ben Atta M; Abou El Makarim S; Zouari MB; Ben Rhouma S
Tunis Med; 2016 Dec; 94(12):844. PubMed ID: 28994883
[TBL] [Abstract][Full Text] [Related]
43. [A case of percutaneous BCG perfusion therapy for CIS of upper urinary tract CIS after radical cystectomy with ileal neobladder].
Obayashi K; Miki J; Kasai K; Tashiro K; Tsuduki S; Bando S; Ishii G; Suzuki K; Kimura T; Kishimoto K; Egawa S
Hinyokika Kiyo; 2014 Sep; 60(9):443-6. PubMed ID: 25293799
[TBL] [Abstract][Full Text] [Related]
44. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
45. Granulomatous nephritis as a complication of intrarenal bacille Calmette-Guérin therapy.
Soda T; Hori D; Onishi H; Miyakawa M
Urology; 1999 Jun; 53(6):1228. PubMed ID: 10754116
[TBL] [Abstract][Full Text] [Related]
46. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
Brosman SA
Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
[TBL] [Abstract][Full Text] [Related]
47. Fever following intracavitary bacillus Calmette-Guerin therapy for upper tract transitional cell carcinoma.
Schnapp DS; Weiss GH; Smith AD
J Urol; 1996 Aug; 156(2 Pt 1):386-8. PubMed ID: 8683684
[TBL] [Abstract][Full Text] [Related]
48. Results of conservative treatment of upper urinary tract transitional cell carcinoma.
Fujimoto N; Sato H; Mizokami A; Inatomi H; Matsumoto T
Int J Urol; 1999 Aug; 6(8):381-7. PubMed ID: 10466449
[TBL] [Abstract][Full Text] [Related]
49. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
Eure GR; Cundiff MR; Schellhammer PF
J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
[TBL] [Abstract][Full Text] [Related]
50. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
51. Treatment of carcinoma in situ of the urethra with intraurethral instillations of bacillus Calmette-Guérin. Case report and review of literature.
Witjes JA; Debruyne FM; van der Meijden AP
Eur Urol; 1991; 20(2):170-2. PubMed ID: 1752279
[TBL] [Abstract][Full Text] [Related]
52. [Transitional cell carcinoma in prostate after intravesical instillation of Bacillus Calmette-Guerin].
Ito Y; Nishiyama H; Higashi S; Kinoshita H; Ito N; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2004 May; 50(5):335-8. PubMed ID: 15237488
[TBL] [Abstract][Full Text] [Related]
53. [Two cases of successful treatments with steroid for local and systemic hypersensitivity reaction following intravesical instillation of Bacillus Calmette-Guerin].
Shimasaki N; Yamasaki I; Kamada M; Syuin T
Hinyokika Kiyo; 2001 Apr; 47(4):281-4. PubMed ID: 11411106
[TBL] [Abstract][Full Text] [Related]
54. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
55. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
56. Intravesical Bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder.
Ovesen H; Poulsen AL; Steven K
Br J Urol; 1993 Nov; 72(5 Pt 2):744-8. PubMed ID: 8281407
[TBL] [Abstract][Full Text] [Related]
57. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
[TBL] [Abstract][Full Text] [Related]
58. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Brosman SA
J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
[TBL] [Abstract][Full Text] [Related]
59. [A case of interstitial pneumonitis caused by intravesical bacillus Calmette-Guérin instillation].
Horinaga M; Nakamura K; Nishiyama T; Murai M
Hinyokika Kiyo; 1999 Jul; 45(7):493-5. PubMed ID: 10466068
[TBL] [Abstract][Full Text] [Related]
60. [Carcinoma in situ of the bladder involving the prostate with an unusual invasive pattern following BCG therapy: a case report].
Iba A; Kohjimoto Y; Inagaki T; Suzuki A; Fujii R; Senzaki H; Uekado Y; Shinka T
Hinyokika Kiyo; 2005 Oct; 51(10):681-4. PubMed ID: 16285623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
